Selected Posters and Abstracts
Hot Topics and Late Breakers
[PL13.2] Predictors of creatinine (Cr) increase and drug discontinuation in patients receiving tenofovir DF (TDF)
[PL13.3] Impact of a lopinavir/ritonavir (LPV/r) monotherapy on self-reported side effects and global health perception among antiretroviral-naïve patients: 48-week analysis of the MONARK Trial
[PL13.4] Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada